Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

Casdatifan, a HIF-2α inhibitor, shows early clinical activity and good tolerance in patients with previously treated clear cell renal cell carcinoma.

Intended setting of use for genitourinary cancer drug approvals by tumor type, 2020-2024. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not ...

Evaluating cost-effectiveness in the evolving treatment landscape for metastatic urothelial carcinoma.

FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.

Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification.

Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination ...

Avelumab in combination with axitinib was found effective and safe as frontline treatment for advanced RCC in real-world ...

Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that its prostate cancer PET[1] ...

A high omega-3, low omega-6 diet with fish oil led to a significant reduction in a biomarker for prostate cancer progression ...

Accurate calculation of prostate-specific antigen doubling time can be crucial for prostate cancer treatment decisions but is ...